A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Stopped early · Phase 1

Conditions studied: Solid Cancers, Non-Hodgkin's Lymphoma

In brief

This is an open-label, multicenter, Phase I/II study to assess the safety, tolerability, and pharmacokinetics of GDC-0032. The Phase I portion will be divided into two stages. During Stage 1, GDC-0032 will be administered every day orally and at escalating doses in participants with locally advanced or metastatic solid tumors. During Stage 2, GDC-0032 will be administered alone or as combination therapy within indication-specific cohorts. In Phase II of the study, the efficacy and safety of the combination GDC-0032 and fulvestrant will be evaluated in post-menopausal female participants with locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative, hormone receptor-positive breast cancer.

Key facts

Study ID

NCT01296555

Run by

Genentech, Inc.

People needed

674

Starts

2011-03-16

Expected to finish

2021-06-25

Last updated by the study team

2024-07-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Phase I (Cohorts A through D, G, H, T, T2 and X): Histologically documented, locally advanced or metastatic solid malignancy or NHL that has progressed or failed to respond to at least one prior regimen and are not candidates for regimens known to provide clinical benefit
• Phase I (Cohorts E and F): Post-menopausal females with locally advanced or metastatic hormone receptor-positive breast cancer that has progressed or failed to respond to at least one prior endocrine therapy in the adjuvant or metastatic setting
• Phase I (Cohorts J through S): Post-menopausal females with HER2-negative, hormone-receptor positive breast cancer that has progressed or failed to response to at least one prior endocrine therapy in the adjuvant or metastatic setting
• Phase II: Post-menopausal female participants with locally advanced or metastatic HER2-negative, hormone receptor-positive breast cancer
• Phase I (Cohorts A through S) and Phase II: Evaluable or measurable disease per RECIST version 1.1
• Phase I (Cohorts T, and T2): Greater than or equal to (>/=) 1 bi-dimensionally measurable lesion on computed tomography (CT) scan
• Phase I (Cohort T): Participants with non-Hodgkin's lymphoma, regardless of PIK3CA mutation status
• Phase 1 (Cohort T2): Participants with diffuse large B-cell lymphoma (DLBCL), regardless of PIK3CA mutation status
• Phase I (Cohort X): Participants with PIK3CA-mutant tumors and measurable disease per RECIST v1.1
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at Screening
• Life expectancy of >/= 12 weeks
• Adequate hematologic and organ function within 28 days prior to initiation of study treatment
• Documented willingness to use an effective means of contraception for both men and women while participating in the study

You may not qualify if…

• Known and untreated, or active central nervous system (CNS) metastases (progressing or requiring treatment)
• Active congestive heart failure or ventricular arrhythmia requiring medication
• Participants requiring any daily supplemental oxygen
• Active inflammatory disease requiring immunosuppressants, including small or large intestinal inflammation such as Crohn's disease or ulcerative colitis
• Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
• Treatment with chemotherapy less than or equal to (</=) 3 weeks before study treatment
• Oral endocrine therapy </= 2 weeks before study treatment
• Treatment with investigational drug </= 3 weeks or 5 half-lives before study treatment
• Treatment with biologic therapy </= 3 weeks before study treatment
• Treatment with kinase inhibitors </= 2 weeks before study treatment
• Radiation therapy (other than radiation to bony metastases) as cancer therapy </= 4 weeks before study treatment
• Palliative radiation therapy to bony metastases </= 2 weeks before study treatment
• Major surgery </= 4 weeks before study treatment
• Any other diseases, active or uncontrolled pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may affect the interpretation of the results, or renders the participant at high risk from treatment complications (examples include but are not limited to clinically significant non-healing wound, active bleeding, or ongoing fistula or active tuberculosis infection)

Where it is running

• TGen Clinical Research Srvs — Scottsdale, Arizona, United States
• University of Arizona Cancer Center — Tucson, Arizona, United States
• University of California Irvine Medical Center — Orange, California, United States
• UC Davis; Comprehensive Cancer Center — Sacramento, California, United States
• Sutter Health — San Francisco, California, United States
• Yale University — New Haven, Connecticut, United States
• Florida Cancer Specialists - Fort Myers (New Hampshire Ct) — Fort Myers, Florida, United States
• Sarah Cannon Res Inst; FL — Sarasota, Florida, United States
• Univ of Chicago — Chicago, Illinois, United States
• Barbara Ann Karmanos Cancer Institute — Detroit, Maine, United States
• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
• Dana Farber Cancer Inst. — Boston, Massachusetts, United States
• Washington University; Division of Oncology — St Louis, Missouri, United States
• New York Oncology Hematology, P.C. — Albany, New York, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Sarah Cannon Res Inst; OK — Oklahoma City, Oklahoma, United States
• West Cancer Center — Germantown, Tennessee, United States
• Sarah Cannon Res Inst; TN Onc — Nashville, Tennessee, United States
• Vanderbilt Breast Center; Vanderbilt Health Pharmacy — Nashville, Tennessee, United States
• Vanderbilt — Nashville, Tennessee, United States
• Texas Cancer Center — Abilene, Texas, United States
• Mary Crowley Cancer Rsch Ctr — Dallas, Texas, United States
• Baylor Sammons Cancer Center — Dallas, Texas, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• USO - Tyler Cancer Ctr — Tyler, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.